Clinical trial · no report yet · Phase 2/Phase 3
AML18
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations
- NCT02272478 ↗
- Unknown
- Cardiff University
- 12 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 6 | |
| YouTube | 4 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Trial for Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome
- Phase
- Phase 2/Phase 3
- Status
- Unknown
- Conditions
- Acute Myeloid Leukaemia; Myelodysplastic Syndrome
- Interventions
- Arm A Mylotarg plus DA Versus CPX-351; Arm B Vosaroxin and Decitabine; Arm D Small molecule or Not; Arm C DA V FLAG-Ida V DAC; Arm E CPX-351 (200 V 300); Arm F DA V IDAC
- Arms
- Arm A · Active comparator
- Arm B · Active comparator
- Arm C · Active comparator
- Arm D · Active comparator
- Arm E · Active comparator
- Arm F · Active comparator
- Enrollment
- 1,600 (estimated)
- Primary outcomes
- Overall survival
- Complete remission (CR + CRi) achievement and reasons for failure (for induction questions)
- Duration of remission, relapse rates and deaths in first CR
- Toxicity, both haematological and non-haematological
- Supportive care requirements (and other aspects of health economics)
- Sponsor
- Cardiff University with Cancer Research UK
- Start
- Oct 30, 2014
- Primary completion
- Feb 2021 (estimated)
- Results posted
- No
- Registry record
- NCT02272478 · updated Jan 23, 2020
Publications
linked from the registry- Knapper S, Dillon LW, Babu M, Thomas A, Thomas I, Hourigan CS, Andrew G, Dillon R, Gilkes A, Marquez Almuina N, King S, McCarthy N, Bahr R, Al-Ali RW, Stone L, Coats T, Byrne J, Green S, Overgaard UM, Sellar RS, Dennis M, Mehta P, Hills R, Freeman SD, Russell NH. CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial. Blood. 2026 Mar 5;147(10):1048-1057. doi: 10.1182/blood.2025031006. PubMed 41237344